Ethris Revenue and Competitors

Planegg,

Location

#9737

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Ethris's estimated annual revenue is currently $12.2M per year.(i)
  • Ethris's estimated revenue per employee is $155,000

Employee Data

  • Ethris has 79 Employees.(i)
  • Ethris grew their employee count by 46% last year.

Ethris's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Ethris?

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients' cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.

keywords:N/A

N/A

Total Funding

79

Number of Employees

$12.2M

Revenue (est)

46%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ethris News

2022-04-19 - mRNA Vaccine Market Size, Scope And Forecast | Argos ...

Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech,...

2022-04-17 - mRNA Vaccine Market Size And Forecast | Argos Therapeutics ...

Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech,...

2022-02-22 - Ethris Raises €23M to Make Inhaled Respiratory Therapies from ...

Unlike marketed mRNA vaccines, which are delivered via an injection, Ethris' therapies are designed to be inhalable. The company uses lipid...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.4M93N/AN/A
#2
$32.6M2108%N/A
#3
$116M46228%N/A
#4
$162.7M121933%N/A